Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
2000 2
2013 1
2017 1
2018 2
2019 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases.
Babiker HM, Byron SA, Hendricks WPD, Elmquist WF, Gampa G, Vondrak J, Aldrich J, Cuyugan L, Adkins J, De Luca V, Tibes R, Borad MJ, Marceau K, Myers TJ, Paradiso LJ, Liang WS, Korn RL, Cridebring D, Von Hoff DD, Carpten JD, Craig DW, Trent JM, Gordon MS. Babiker HM, et al. Among authors: paradiso lj. Invest New Drugs. 2019 Aug;37(4):636-645. doi: 10.1007/s10637-018-0668-8. Epub 2018 Sep 28. Invest New Drugs. 2019. PMID: 30264293 Free PMC article. Clinical Trial.
FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells.
Mima S, Kakinuma C, Higuchi T, Saeki K, Yamada T, Uematsu R, Ishino M, Kito N, Nishikawa H, Kuniyoshi H, Matsumoto T, Fujiwara H, Paradiso LJ, Shimada Y, Iwamura H. Mima S, et al. Among authors: paradiso lj. J Pharmacol Exp Ther. 2018 Jul;366(1):125-135. doi: 10.1124/jpet.118.248740. Epub 2018 Apr 13. J Pharmacol Exp Ther. 2018. PMID: 29653962
Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks.
Roberts JD, Shibata S, Spicer DV, McLeod HL, Tombes MB, Kyle B, Carroll M, Sheedy B, Collier MA, Pithavala YK, Paradiso LJ, Clendeninn NJ. Roberts JD, et al. Among authors: paradiso lj. Cancer Chemother Pharmacol. 2000;45(5):423-7. doi: 10.1007/s002800051012. Cancer Chemother Pharmacol. 2000. PMID: 10803927 Clinical Trial.
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ. Muggia FM, et al. Among authors: paradiso lj. J Clin Oncol. 1997 Mar;15(3):987-93. doi: 10.1200/JCO.1997.15.3.987. J Clin Oncol. 1997. PMID: 9060537 Clinical Trial.